Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 45, Issue 3, 2010, Pages 326-334

  Nishida, Chika ^a   Uto, Hirofumi ^a   Oketani, Makoto ^a   Tokunaga, Koki ^a   Nosaki, Tsuyoshi ^a   Fukumoto, Mayumi ^a   Oku, Manei ^a   Sogabe, Atsushi ^a   Moriuchi, Akihiro ^a   Ido, Akio ^a   Tsubouchi, Hirohito ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

ALT; HCV; Hemodialysis; Thrombocytopenia; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; URSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; ALANINE TRANSAMINASE; CHOLAGOGUES AND CHOLERETICS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET COUNT; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 77950459800     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0149-0     Document Type: Article

References (46)

1. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle GH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631-657
2. Batty DS Jr, Swanson SJ, Kirk AD, Ko CW, Agodoa LY. Abbott KC: Hepatitis C virus seropositivity at the time of renal transplantation in the United States: Associated factors and patient survival. Am J Transplant. 2001;1:179-184
3. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291-1299
4. Dussol B, Berthezene P, Brunet P, Roubicek C. Berland Y: Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. Am J Kidney Dis. 1995;25:399-404.
5. Anonymous. The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Aphersis Dial 2003; 7, 3-35.
6. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10. (Pubitemid 34700756)
7. Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004;17:310-319 (Pubitemid 39107657)
8. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004-1010 (Pubitemid 32436573)
9. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int. 1996;50:1013-1018 (Pubitemid 26302692)
10. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271-1277 (Pubitemid 40040073)
11. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-56.
12. Ghany MG, Kleiner DE, AlterH, Doo E, Khokar F,Promrat K,etal. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97-104.
13. Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, et al. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer. 2006;119:192-195
14. Roth D. Hepatitis C virus: the nephrologist's view. Am J Kidney Dis. 1995;25:3-16.
15. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J. 2004;328:983-986
16. Furusyo N, Hayashi J, Kanamoto-Tanaka Y, Ariyama I, Etoh Y, Shigematsu M, et al. Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-years study. Dig Dis Sci. 2000;45:2221-2228
17. Lopes EP, Gouveia EC, Albuquerque AC, Sette LH, Mello LA, Moreira RC, et al. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol. 2006;35:298-302.
18. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526
19. Hu KQ, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol. 2005;100:2010-2018
20. Kose S, Gurkan A, Akman F, Kelesoglu M, Uner U. Treatment of hepatitis C in hemodialysis patients using pegylated interferon a-2a in Turkey. J Gastroeterol. 2009;44:353-358
21. Russo MW, Goldsweig C, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroen-terol. 2003;98:1610-1615
22. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, et al. The tolerance and efficacy of interferon-a in haemodialysis patients with HCV infection: a multicenter prospective study. Nephrol Dial Transplant. 2001;16:1017-1023
23. Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut. 2007;56:1747-1753
24. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009;24:1598-1603
25. Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, et al. Hepatitis C virus infection in 2,744 hemodial-ysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol. 2005;76:498-502.
26. Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007;11:411-441
27. Gafter U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron. 1987;45:207-210
28. Ando M, Iwamoto Y, Suda A, Tsuchiya K, Nihei H. New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood. 2001;97:915-921
29. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28:82-85
30. Wallner SF, Ward HP, Vautrin R, Alfrey AC, Mishell J. The anemia of chronic renal failure: in vitro response of bone marrow to erythropoietin. Proc Soc Exp Biol Med. 1975;149:939-944
31. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodi-alysis therapy. J Am Soc Nephrol. 2000;11:1896-1902
32. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832
33. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524
34. Chu CW, Hwang SJ, Lu RH, Lai CR, Luo JC, Wang YJ, et al. Clinical significance of the changes of platelet counts and serum thrombopoietin levels in chronic hepatitis C patients treated with different doses of consensus interferon. Hepatol Res. 2002;24:236.
35. Kopple JD, Mercurio K, Blumenkrantz MJ, Jones MR, Tallos J, Roberts C, et al. Daily requirement for pyridoxine supplements in chronic renal failure. Kidney Int. 1981;19:694-704.
36. Van Lente F, McHugh A, Pippenger CE. Carbamylation of apo-aspartate aminotransferase: a possible mechanism for enzyme inactivation in uremic patients. Clin Chem. 1986;32:2107-2108
37. Warnock LG, Stone WJ, Wagner C. Decreased aspartate ami-notransferase ("SGOT") activity in serum of uremic patients. Clin Chem. 1974;20:1213-1216
38. Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol. 1999;94:3576-3582
39. Contreras AM, Ruiz I, Polanco-Cruz G, Monteón FJ, Celis A, Vázquez G, et al. End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. Ann Hepatol. 2007;6:48-54.
40. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997;26:1393-1398
41. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007;37:239-247
42. Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat. 2006;13:290-296
43. Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005;43:599-605.
44. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology. 1999;116:378-386
45. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174-181
46. Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, et al. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepat. 2000;7:343-351